Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Emily M. Leproust reported multiple sales of Common stock. The filings list open‑market dispositions on several dates between 04/21/2026 and 06/08/2026 with individual trades such as 24,282 shares on 05/26/2026 for $1,580,245.85 and 25,017 shares on 05/27/2026 for $1,633,407.46. The excerpt also records a restricted stock vesting of 1,688 shares on 06/18/2026.
Issuer reported insider sales and a restricted-stock vesting. The filing lists a Restricted Stock Vesting of 346 shares on 06/18/2026 recorded as compensation. It also discloses multiple sales by Dennis H. Cho: 1,962 shares on 05/04/2026, 1,642 shares on 05/21/2026, 14,205 shares on 05/29/2026, and 402 shares on 06/08/2026, with proceeds shown in the filing for each sale.
Form 144 notice: proposed sale of Common Stock related to TWST. The filing lists a proposed sale of 291 shares tied to restricted stock vesting on 06/18/2026 described as Compensation. The filing also reports multiple sales by Paula Green during the past three months: 1,116 shares on 05/04/2026, 1,399 shares on 05/21/2026, 884 shares on 06/08/2026, and 26,137 shares on 06/15/2026, each with the dollar amounts shown in the excerpt.
Twist Bioscience filed a shelf registration and a sales agreement to offer up to $200,000,000 of its common stock for issuance from time to time under an at-the-market program. The company may sell shares through TD Securities (USA) LLC ("TD Cowen") as sales agent or principal.
The prospectus clarifies that sales will be at market prices and the timing, amounts and prices will vary by placement notices. Proceeds from shares sold under the Sales Agreement will be used for general corporate purposes, including working capital, with management retaining broad discretion. The prospectus incorporates Twist’s SEC reports, shows 62,154,412 shares outstanding as of March 31, 2026, and provides illustrative figures using a last reported price of $84.95 per share.
Twist Bioscience Corp SVP of Human Resources Paula Green reported option exercises and share sales. On June 15, 2026, she exercised employee stock options for 26,137 shares of common stock at an exercise price of $23.33 per share. The same day, she made open‑market sales of 24,109 shares at a weighted average price of $81.6233 and 2,028 shares at a weighted average price of $82.1655. After these transactions, she directly owned 120,705 shares of Twist Bioscience common stock.
TWST proposes sale of 26,137 shares of Common Stock via stock option exercise. The filing states the sale date as 06/15/2026 and lists Fidelity Brokerage Services LLC as the broker-dealer. The filing also lists recent dispositions by Paula Green totaling 3,696 shares on 03/20/2026, 05/04/2026, 05/21/2026, and 06/08/2026 with cash amounts shown for each sale.
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 402 shares of common stock at an average price of $69.8442 per share. After this transaction, he directly holds 119,692 shares. According to the disclosure, the sale was mandated to cover tax withholding on vesting Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade.
Twist Bioscience Corp SVP of Human Resources Paula Green reported a small mandated share sale tied to tax withholding. She sold 884 shares of common stock at an average price of $69.8442 per share to cover taxes due on vesting Restricted Stock Units, under a required “sell to cover” election in the company’s equity incentive plans. After this non-discretionary transaction, she directly holds 120,705 shares.
Twist Bioscience Corp reported that Chief Executive Officer Emily M. Leproust sold 2,265 shares of common stock at $69.8442 per share. According to the disclosure, these shares were sold to cover tax withholding obligations related to vesting Restricted Stock Units under the company’s equity incentive plans, rather than as discretionary trades.
After this tax-related sale, Leproust directly holds 844,607 shares of common stock. She also holds employee stock options to purchase 64,950 shares of common stock at an exercise price of $67.85 per share, which are immediately exercisable and expire on August 31, 2030.
Twist Bioscience Corp's Chief Accounting Officer, Robert F. Werner, reported routine share movements in common stock. On June 8, 2026, he sold a total of 1,359 shares in two open-market transactions at prices of $69.07 and $69.8442 per share.
According to the disclosure, these sales were required to cover tax withholding obligations tied to vesting Restricted Stock Units under the company’s equity plans, and were not discretionary trades. Werner also made a bona fide gift of 500 shares to a charitable organization and continues to hold 46,327 shares directly.